Sanara MedTech (NASDAQ:SMTI) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Sanara MedTech (NASDAQ:SMTI) released its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.10, Zacks reports. Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%.

Sanara MedTech Stock Up 6.2 %

SMTI stock opened at $35.69 on Tuesday. The company has a market cap of $311.97 million, a price-to-earnings ratio of -36.05 and a beta of 1.37. Sanara MedTech has a twelve month low of $26.00 and a twelve month high of $39.08. The business has a 50 day moving average price of $34.43 and a two-hundred day moving average price of $33.84. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76.

Analysts Set New Price Targets

Several equities research analysts have issued reports on SMTI shares. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Sanara MedTech in a report on Thursday, January 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $44.00 price objective on shares of Sanara MedTech in a research report on Wednesday, January 22nd.

About Sanara MedTech

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.